US stock futures dip as Nvidia earnings spark little cheer
Ryan M. Bartolucci, the Chief Accounting Officer of Tempus AI , Inc. (NASDAQ:TEM), sold 6,059 shares of the company's Class A common stock on February 13, 2025. The timing is notable as TEM shares have surged over 21% in the past week alone, currently trading at $89.44 and near their 52-week high. The shares were sold at a price of $80 each, resulting in a total transaction value of $484,720. Following this sale, Bartolucci holds 47,000 shares of Tempus AI, now valued at approximately $4.2 million. This transaction was executed under a Rule 10b5-1 trading plan, which was adopted on June 14, 2024. According to InvestingPro analysis, the stock is currently showing overbought signals, with the company's market capitalization reaching $13.2 billion after a remarkable 95% gain over the past six months.
In other recent news, Tempus AI has seen significant developments. The company's stock rating was upgraded by TD Cowen, which also raised its price target to $74. This upgrade follows the acquisition of Ambry Genetics, a move that analysts believe will enhance Tempus AI's product offerings and allow for entry into new markets. The acquisition, which adds a profitable germline testing laboratory with over $300 million in revenue to Tempus AI's portfolio, is expected to lead to positive free cash flow.
In addition to the Ambry Genetics acquisition, Tempus AI has also launched a personal health concierge app named Olivia. This app is designed to centralize patient health data and provide actionable AI-driven insights, marking a significant step in advancing precision medicine and enhancing patient care.
Tempus AI has also been involved in a multi-year agreement with Genialis to validate new RNA-based biomarker algorithms using Tempus's multimodal dataset across different cancer types. These recent developments highlight Tempus AI's ongoing commitment to leveraging advanced technologies to improve patient care and outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.